Page 40 - PCC15
P. 40
Moral obligation
Responsible innovation requires making potentially risky reproductive technologies the subject of research, ideally proceeding through the steps of preclinical investigations, clinical trials and (long-term) follow- up studies.
The liability in this is often left to the patient by means of ‘informed consent’. But it is simply too easy to just hide behind the demand of the patient. The problem here is that a patient could agree with being treated with a technique of unknown effectiveness, but the clinician still remains responsible for what he or she does.
Dondorp and de Wert, HR (2011)
Who benefits from PGS?
• The companies!
• PGS/CCS at CCRM in 2013
– 3309 cycles * 0.85 (cycles with CCS) * $ 8975 = $ 25,246,675
http://www.colocrm.com, http://www.sart.org, Repping, Best of ASRM/ESHRE, New York (2015)
$ 8975
Page 34 of 125
40
